Alnylam's Cardiac Drug Program Faces Scrutiny at European Cardiology Congress
Source Summary
Alnylam Pharmaceuticals faces a significant moment at the European Society of Cardiology Congress beginning Friday in Munich, where its heart drug program will be a focal point of discussion.
Why it matters
The congress provides a major platform for Alnylam to address challenges with its cardiac drug development program before the medical and investment community.
